ReviewInternational journal of nanomedicine2026
The Application of Nanomaterials in the Detection of Liver Cancer Biomarkers.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer is one of the malignant tumors with high global incidence and mortality rates, with hepatocellular carcinoma (HCC) accounting for 90% of primary liver cancer cases. Due to the lack of specific symptoms in early-stage liver cancer, diagnosis is often delayed, leading to the majority of patients being identified at intermediate to advanced stages with poor prognoses. Early diagnosis is critical for improving patient survival; however, conventional diagnostic methods face limitations such as low sensitivity and insufficient specificity. Nanomaterials have demonstrated great potential in laboratory research to overcome the limitations of traditional detection technologies by virtue of their unique physicochemical properties. However, most of these relevant studies are still in the laboratory stage and require large-scale clinical validation. This review systematically summarizes the innovative applications of nanomaterials in liver cancer biomarker diagnostics, focusing on their mechanisms for improving detection performance, including signal amplification, targeted recognition, and system optimization. It highlights specific applications of nanomaterials in biomarker detection, discusses current challenges in nanodiagnostic technologies, and explores future development trends, aiming to provide novel perspectives for the diagnosis of liver cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.